Prostate-Specific Antigen (PSA) Testing: Principles, Methods, and Clinical Applications

Prostate-specific antigen (PSA) testing is a quantitative laboratory assay that measures the concentration of PSA in serum or plasma to support prostate cancer screening, diagnostic workup, and post-treatment monitoring. Modern immunoassay platforms operated under ISO 15189-accredited laboratory conditions deliver sensitive, reproducible results traceable to WHO International Standards. This article provides a comprehensive technical overview of PSA determination, covering sample requirements, analytical parameters, test methods, quality standards, and clinical applications.

Technical Overview

Prostate-specific antigen (PSA), formally designated kallikrein-related peptidase 3 (KLK3), is a 287-amino-acid, single-chain glycoprotein of approximately 30–34 kDa belonging to the kallikrein family of serine proteases. It is synthesized almost exclusively by the epithelial cells of the prostate gland, where its physiological role is to liquefy the seminal coagulum through proteolytic cleavage of semenogelin proteins, thereby releasing motile spermatozoa.

Under normal physiological conditions, only trace amounts of PSA enter the systemic circulation and serum concentrations remain low. Disruption of the prostatic architecture—caused by malignant transformation, benign prostatic hyperplasia (BPH), inflammatory disease (prostatitis), or mechanical manipulation—increases the passage of PSA into the bloodstream and elevates serum levels. PSA has a serum half-life of approximately two to three days, which is clinically relevant when timing follow-up measurements after prostate surgery or after resolution of a transient elevation.

PSA determination is one of the most widely performed tumor marker assays worldwide. Quantitative results are reported in nanograms per milliliter (ng/mL), and assay calibration is traceable to WHO International Standards (WHO 96/670 for total PSA and WHO 96/668 for free PSA) in accordance with the metrological traceability requirements of ISO 17511. Testing is performed by accredited third-party laboratories and clinical laboratories complying with ISO 15189, while reagents and instruments are manufactured under quality management systems certified to ISO 13485 and regional IVD regulations such as EU IVDR 2017/746.

• Analytes: total PSA (tPSA), free PSA (fPSA), complexed PSA (cPSA)
• Matrix: serum or plasma
• Reporting unit: ng/mL
• Conventional decision threshold: 4.0 ng/mL, with age-specific reference intervals also applied
• Limit of detection of modern platforms: typically ≤0.008–0.1 ng/mL

Testing Samples

Serum

Serum is the standard sample matrix. Venous blood is collected into plain tubes or serum separator tubes, allowed to clot for 20–30 minutes at room temperature, and centrifuged to separate the serum. A typical minimum volume is 0.5–1.0 mL. Gross hemolysis, lipemia, and icterus should be avoided because they may interfere with optical detection systems used on automated analyzers.

Plasma

Plasma anticoagulated with K2/K3-EDTA or lithium heparin is acceptable on many automated platforms, subject to validation documented in the assay instructions for use. Internal quality control materials and reference intervals must match the matrix being tested.

Sample Handling and Stability

Separated serum or plasma is generally stable for up to 24 hours at room temperature and for 48–72 hours at 2–8 °C, depending on the assay system. For longer storage, samples should be aliquoted and frozen at −20 °C or preferably −70 °C, and more than two freeze–thaw cycles should be avoided. Pre-analytical precautions include deferring sampling for at least 48 hours after ejaculation or vigorous exercise such as cycling, at least one week after digital rectal examination or urethral instrumentation, and approximately four to six weeks after prostate biopsy, transurethral resection, or resolution of a urinary tract infection.

Testing Items

PSA measurement profiles can be tailored to the clinical question, and the principal reported parameters are summarized below.

• Total PSA (tPSA): the sum of free and complexed forms; conventional reference value below 4.0 ng/mL, with age-specific upper limits commonly applied (40–49 years: 2.5; 50–59: 3.5; 60–69: 4.5; 70–79: 6.5 ng/mL).
• Free PSA (fPSA): the unbound fraction, typically 5–35% of total PSA, interpreted chiefly as a ratio.
• Complexed PSA (cPSA): the fraction bound to protease inhibitors such as alpha-1-antichymotrypsin.
• Free-to-total PSA ratio (f/t): in the diagnostic gray zone (tPSA 4–10 ng/mL), an f/t ratio below 10–15% is associated with a higher probability of cancer, whereas a ratio above 25% is more consistent with benign disease.
• PSA density (PSAD): serum tPSA divided by prostate volume measured by ultrasound; values above 0.15 ng/mL/cm³ raise suspicion of malignancy.
• PSA velocity (PSAV) and PSA doubling time (PSADT): rate-of-change metrics calculated from serial measurements; a sustained velocity above 0.75 ng/mL per year is considered clinically significant.

Testing Methods

All routine PSA assays are two-site (sandwich) immunoassays that use capture and detection antibodies directed against non-overlapping epitopes of the PSA molecule. Equimolar and reproducible detection of both free and complexed PSA is a key performance characteristic of modern kits. Principal analytical formats include the following:

• Chemiluminescent microparticle immunoassay (CMIA): paramagnetic microparticle solid phase with chemiluminescent labels; fully automated, high-throughput, with detection limits down to approximately 0.01 ng/mL.
• Electrochemiluminescence immunoassay (ECLIA): ruthenium-complex-labeled tracers with magnetic bead capture on automated analyzers, offering wide dynamic range and excellent precision.
• Enzyme-linked immunosorbent assay (ELISA): microplate HRP/TMB colorimetric format suitable for smaller laboratories and research settings, with longer turnaround times.
• Latex-enhanced immunoturbidimetry: particle agglutination format adaptable to open clinical chemistry analyzers.
• Immunoradiometric assay (IRMA): the historical iodine-125 labeled method, now largely replaced by non-isotopic platforms.
• Point-of-care rapid tests: fluorescent or immunochromatographic cassettes providing semi-quantitative or quantitative results within 10–20 minutes for near-patient testing.

Method Validation and Quality Control

Assays are validated and controlled in line with CLSI evaluation protocols (EP05 for precision, EP06 for linearity, EP07 for interference, EP09 for method comparison, and EP17 for detection capability) together with the management requirements of ISO 15189. Laboratories run at least two levels of internal quality control in each analytical session, apply multirule statistical QC strategies, and participate in external quality assessment schemes. Known analytical interferences—including heterophile antibodies, human anti-mouse antibodies, high-dose biotin, and the high-dose hook effect at extremely elevated PSA concentrations—are managed through blocking reagents, automatic dilution protocols, and confirmatory retesting.

Applications

• Prostate cancer screening: early detection programs for men aged 50 and above, starting at 40–45 for high-risk individuals with a family history or of African ancestry, typically combined with digital rectal examination and shared clinical decision-making.
• Diagnostic workup: risk stratification in conjunction with multiparametric MRI and PSA isoforms such as [-2]proPSA, guiding the decision to proceed to systematic or targeted prostate biopsy.
• Post-treatment monitoring: after radical prostatectomy, PSA should fall to undetectable levels, and a confirmed value of 0.2 ng/mL or higher defines biochemical recurrence; serial PSA also tracks response during radiotherapy, hormonal therapy, and active surveillance.
• Benign disease evaluation: differential assessment of benign prostatic hyperplasia and monitoring of inflammatory prostatic conditions.
• Forensic science: immunological detection of PSA in biological stains as a marker of seminal fluid.
• Health examinations and research: inclusion in men's health screening panels, epidemiological studies, and clinical trials.

Because PSA is organ-specific but not cancer-specific, interpretation should always be performed by qualified physicians in combination with clinical findings, imaging results, and histopathological confirmation.

FAQ

What is considered a normal PSA level?

The traditional cutoff is below 4.0 ng/mL, but age-specific thresholds ranging from 2.5 to 6.5 ng/mL and the rate of change over time provide a more individualized and clinically useful interpretation.

Does an elevated PSA always mean prostate cancer?

No. Benign prostatic hyperplasia, prostatitis, urinary retention, recent ejaculation, catheterization, and cycling can all raise PSA. In the 4–10 ng/mL gray zone, only roughly one in four men is found to have prostate cancer on biopsy.

How should I prepare for a PSA test?

Fasting is not required. Avoid ejaculation and vigorous exercise for 48 hours before sampling, and postpone testing for at least one week after digital rectal examination or urinary instrumentation and four to six weeks after prostate biopsy or a urinary tract infection.

When should screening begin and how often should it be repeated?

For men at average risk, screening should be discussed from age 50; for high-risk men, from age 40–45. Measurement intervals of one to two years are typical, depending on the baseline level and recommendations of major urological guidelines.

What is the difference between free and total PSA?

Total PSA measures both the unbound and the protein-bound fractions, while free PSA measures only the unbound form. A lower proportion of free PSA relative to total PSA increases the suspicion of cancer when total PSA falls in the diagnostic gray zone.

How accurate are the results and how long does testing take?

Modern chemiluminescent and electrochemiluminescent platforms achieve within-run and between-run coefficients of variation typically below 5–10% with detection limits at or below 0.01 ng/mL. In accredited third-party laboratories, validated results are usually reported within 24 hours of sample receipt.